Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.14 AUD
−174.23 M AUD
388.40 M AUD
64.71 M
About MAYNE PHARMA GROUP LIMITED
Sector
CEO
Shawn Patrick O'Brien
Headquarters
Salisbury
Website
Founded
2005
ISIN
AU000000MYX0
FIGI
BBG000BLN6N6
Mayne Pharma Group Ltd. engages in the development and manufacture of proprietary and generic products. It operates through the following segments: Generic Products, Specialty Products, Metrics Contract Services, and Mayne Pharma International. The Generic Products segment is involved in the manufacture and distribution of generic and branded pharmaceutical products. The Metrics Contract Services segment provides contract pharmaceutical services. The Specialty Products segment includes the distribution of branded pharmaceutical products. The Mayne Pharma International segment manufactures and sells branded and generic pharmaceutical products and provides contract manufacturing services to third party customers within Australia. The company was founded in 1845 and is headquartered in Salisbury, Australia.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of MYX is 5.10 AUD — it has increased by 0.23% in the past 24 hours. Watch MAYNE PHARMA GROUP LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange MAYNE PHARMA GROUP LIMITED stocks are traded under the ticker MYX.
MYX stock has risen by 3.02% compared to the previous week, the month change is a −3.70% fall, over the last year MAYNE PHARMA GROUP LIMITED has showed a 26.55% increase.
We've gathered analysts' opinions on MAYNE PHARMA GROUP LIMITED future price: according to them, MYX price has a max estimate of 6.25 AUD and a min estimate of 5.93 AUD. Watch MYX chart and read a more detailed MAYNE PHARMA GROUP LIMITED stock forecast: see what analysts think of MAYNE PHARMA GROUP LIMITED and suggest that you do with its stocks.
MYX stock is 16.70% volatile and has beta coefficient of 2.15. Track MAYNE PHARMA GROUP LIMITED stock price on the chart and check out the list of the most volatile stocks — is MAYNE PHARMA GROUP LIMITED there?
Today MAYNE PHARMA GROUP LIMITED has the market capitalization of 376.03 M, it has decreased by −5.49% over the last week.
Yes, you can track MAYNE PHARMA GROUP LIMITED financials in yearly and quarterly reports right on TradingView.
MAYNE PHARMA GROUP LIMITED is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
MYX earnings for the last half-year are 0.00 AUD per share, whereas the estimation was −0.22 AUD, resulting in a 100.45% surprise. The estimated earnings for the next half-year are −0.14 AUD per share. See more details about MAYNE PHARMA GROUP LIMITED earnings.
MAYNE PHARMA GROUP LIMITED revenue for the last half-year amounts to 200.45 M AUD, despite the estimated figure of 202.00 M AUD. In the next half-year revenue is expected to reach 211.35 M AUD.
MYX net income for the last half-year is −103.68 M AUD, while the previous report showed −70.55 M AUD of net income which accounts for −46.96% change. Track more MAYNE PHARMA GROUP LIMITED financial stats to get the full picture.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MAYNE PHARMA GROUP LIMITED EBITDA is −9.38 M AUD, and current EBITDA margin is −2.41%. See more stats in MAYNE PHARMA GROUP LIMITED financial statements.
Like other stocks, MYX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MAYNE PHARMA GROUP LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MAYNE PHARMA GROUP LIMITED technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MAYNE PHARMA GROUP LIMITED stock shows the neutral signal. See more of MAYNE PHARMA GROUP LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.